Table 8 Drug-related adverse events in metastatic renal cell carcinoma patients with post-treatment hypoalbuminemia and normal serum albumin level
Drug-related adverse event | Post-treatment hypoalbuminemia (albumin level < 36.4 g/L) group | Normal serum albumin level (albumin level ≥36.4 g/L) group | P value* | ||||
|---|---|---|---|---|---|---|---|
Any grade | Grade 1–2 | Grade 3–4 | Any grade | Grade 1–2 | Grade 3–4 | ||
Hand–foot syndrome | 22 (57.9) | 22 (57.9) | 0 (0.0) | 99 (67.8) | 90 (61.6) | 9 (6.2) | 0.251 |
Diarrhea | 20 (52.6) | 20 (52.6) | 0 (0.0) | 78 (53.4) | 73 (50.0) | 5 (3.4) | 0.930 |
Nausea | 20 (52.6) | 20 (52.6) | 0 (0.0) | 54 (37.0) | 54 (37.0) | 0 (0.0) | 0.080 |
Fatigue | 17 (44.7) | 17 (44.7) | 0 (0.0) | 61 (41.8) | 61 (41.8) | 0 (0.0) | 0.743 |
Hypertension | 17 (44.7) | 17 (44.7) | 0 (0.0) | 42 (28.7) | 38 (26.0) | 4 (2.7) | 0.060 |
Anemia | 12 (29.6) | 10 (26.3) | 2 (5.3) | 16 (11.0) | 16 (11.0) | 0 (0.0) | 0.002 |
Thrombocytopenia | 11 (29.0) | 11 (29.0) | 0 (0.0) | 29 (19.9) | 27 (18.5) | 2 (1.4) | 0.227 |
Leukocytopenia | 8 (21.1) | 8 (21.1) | 0 (0.0) | 29 (19.9) | 27 (18.5) | 2 (1.4) | 0.871 |
Elevation of ALT | 8 (21.0) | 8 (21.1) | 0 (0.0) | 16 (11.0) | 15 (10.3) | 1 (0.7) | 0.170 |
Alopecia | 6 (15.8) | 6 (15.8) | 0 (0.0) | 11 (7.5) | 11 (7.5) | 0 (0.0) | 0.211 |
Hypothyroidism | 3 (7.9) | 3 (7.9) | 0 (0.0) | 13 (8.9) | 13 (8.9) | 0 (0.0) | 1.000 |